<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H3596AE7F0A6542DDB8CA7F8B658C21CD" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 3709 IH: Protecting Consumer Access to Generic Drugs Act of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-12-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress>113th CONGRESS</congress><session>1st Session</session><legis-num>H. R. 3709</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action><action-date date="20131211">December 11, 2013</action-date><action-desc><sponsor name-id="R000515">Mr. Rush</sponsor> (for himself, <cosponsor name-id="V000128">Mr. Van Hollen</cosponsor>, and <cosponsor name-id="W000215">Mr. Waxman</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title>To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.</official-title></form><legis-body id="H85E5A878230841F5BCD5022D88D30F5C" style="OLC"><section display-inline="no-display-inline" id="HC9F95EF7514049A6B9F193EDA002F47A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Protecting Consumer Access to Generic Drugs Act of 2013</short-title></quote>.</text></section><section id="HB626B4802FB9473E9037D0F4C614AC73"><enum>2.</enum><header>Unfair and deceptive acts and practices related to new drug applications</header><subsection id="H8A7BF423D6D041EB881B3C9EEE973A15"><enum>(a)</enum><header>Conduct prohibited</header><text display-inline="yes-display-inline">It shall be unlawful for any person to directly or indirectly be a party to any agreement resolving or settling a patent infringement claim in which—</text><paragraph id="HE796B47A47E848EFBE8B9756AD291A1C"><enum>(1)</enum><text>an ANDA filer receives anything of value; and</text></paragraph><paragraph id="H46E4F98782DE4D7D832F801F69597399"><enum>(2)</enum><text>the ANDA filer agrees not to research, develop, manufacture, market, or sell, for any period of time, the drug that is to be manufactured under the ANDA involved and is the subject of the patent infringement claim.</text></paragraph></subsection><subsection commented="no" id="H496F7B4723D74823AE86FAE74796E8F1"><enum>(b)</enum><header>Exceptions</header><text display-inline="yes-display-inline">Notwithstanding subsection (a)(1), subsection (a) does not prohibit a resolution or settlement of a patent infringement claim in which the value received by the ANDA filer includes no more than—</text><paragraph id="H8D3ED0F65EB84CFFA4F9E5E0024F378D"><enum>(1)</enum><text display-inline="yes-display-inline">the right to market the drug that is to be manufactured under the ANDA involved and is the subject of the patent infringement claim, before the expiration of—</text><subparagraph id="H94C9E5429A4F4C739888C6DA5EB78B1C"><enum>(A)</enum><text>the patent that is the basis for the patent infringement claim; or</text></subparagraph><subparagraph id="HFF36F8E252A341D9B32B37FB423550E2"><enum>(B)</enum><text>any other statutory exclusivity that would prevent the marketing of such drug; and</text></subparagraph></paragraph><paragraph id="H0E601617A42748779A5AA902A21DD627"><enum>(2)</enum><text>the waiver of a patent infringement claim for damages based on prior marketing of such drug.</text></paragraph></subsection><subsection id="H2FF738E7309246E9ABD0207FE778709A"><enum>(c)</enum><header>Enforcement</header><text>A violation of subsection (a) shall be treated as an unfair and deceptive act or practice and an unfair method of competition in or affecting interstate commerce prohibited under section 5 of the Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/45">15 U.S.C. 45</external-xref>). The Federal Trade Commission shall enforce this Act in the same manner, by the same means, and with the same jurisdiction as though all applicable terms and provisions of the Federal Trade Commission Act were incorporated into and made a part of this Act.</text></subsection><subsection id="H0192433E89774F4B91833AF1514A3C31"><enum>(d)</enum><header>Definitions</header><text>In this section:</text><paragraph commented="no" id="H41DAE27EE9F140058FCBF2CD3CF0E1CD"><enum>(1)</enum><header>Agreement</header><text>The term <term>agreement</term> means anything that would constitute an agreement for purposes of section 5 of the Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/45">15 U.S.C. 45</external-xref>).</text></paragraph><paragraph commented="no" id="H39A8876B8F7A4533B5CA0C3A45082E04"><enum>(2)</enum><header>Agreement resolving or settling</header><text>The term <term>agreement resolving or settling</term>, in reference to a patent infringement claim, includes any agreement that is contingent upon, provides a contingent condition for, or is otherwise related to the resolution or settlement of the claim.</text></paragraph><paragraph id="H34EDDAEB2FC244ED8F770FEE4AAACEB4"><enum>(3)</enum><header>ANDA</header><text>The term <term>ANDA</term> means an abbreviated new drug application for the approval of a new drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>).</text></paragraph><paragraph id="H3593E705F10E40C794A25382105F43EE"><enum>(4)</enum><header>ANDA filer</header><text display-inline="yes-display-inline">The term <term>ANDA filer</term> means a party that has filed an ANDA with the Food and Drug Administration.</text></paragraph><paragraph commented="no" id="HD6FFAA9737B143E5A1BE9E2618A8B37C"><enum>(5)</enum><header>Patent infringement</header><text>The term <term>patent infringement</term> means infringement of any patent or of any filed patent application, extension, reissuance, renewal, division, continuation, continuation in part, reexamination, patent term restoration, patent of addition, or extension thereof.</text></paragraph><paragraph commented="no" id="HEE9A7952A0D74010993047038AE9266C"><enum>(6)</enum><header>Patent infringement claim</header><text>The term <term>patent infringement claim</term> means any allegation made to an ANDA filer, whether or not included in a complaint filed with a court of law, that its ANDA or drug to be manufactured under such ANDA may infringe any patent.</text></paragraph></subsection></section><section id="H65E494A62F3E4B9B89156689D0A09CAF"><enum>3.</enum><header>FTC Rulemaking</header><text display-inline="no-display-inline">The Federal Trade Commission may, by rule promulgated under <external-xref legal-doc="usc" parsable-cite="usc/5/553">section 553</external-xref> of title 5, United States Code, exempt certain agreements described in section 2 if the Commission finds such agreements to be in furtherance of market competition and for the benefit of consumers. Consistent with the authority of the Commission, such rules may include interpretive rules and general statements of policy with respect to the practices prohibited under section 2.</text></section><section id="H9B0E06FCED204DB1B426978045624390"><enum>4.</enum><header>Forfeiture of 180-day exclusivity period under the FFDCA</header><text display-inline="no-display-inline">Section 505(j)(5)(D)(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(D)(i)</external-xref>) is amended in subclause (V) by inserting <quote>section 2 of the Protecting Consumer Access to Generic Drugs Act of 2013 or</quote> after <quote>that the agreement has violated</quote>.</text></section><section display-inline="no-display-inline" id="H551EBCB6E8714238AD832E4AB2BEB8B1" section-type="subsequent-section"><enum>5.</enum><header>Notice and certification of agreements</header><subsection id="H5EC926CFE6AC47CEAAD1D922063B84E0"><enum>(a)</enum><header>Notice of all agreements</header><text>Section 1112(c)(2) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (<external-xref legal-doc="usc" parsable-cite="usc/21/3155">21 U.S.C. 3155</external-xref> note) is amended by—</text><paragraph id="H8A467394795E4775A65B5604779F2CBB"><enum>(1)</enum><text>striking <quote>the Commission the</quote> and inserting <quote>the Commission (1) the</quote>; and</text></paragraph><paragraph id="H88BC54F849664446B3463961FFC6A398"><enum>(2)</enum><text>inserting before the period at the end the following: <quote>; and (2) a description of the subject matter of any other agreement the parties enter into within 30 days of an entering into an agreement covered by subsection (a) or (b)</quote>.</text></paragraph></subsection><subsection id="H5F986BAC20874DB39E1A6056B072867B"><enum>(b)</enum><header>Certification of agreements</header><text>Section 1112 of such Act is amended by adding at the end the following:</text><quoted-block display-inline="no-display-inline" id="H7F7FA41781B44F6BA523B5A9D1E970F1" style="OLC"><subsection id="H2DECB867A03045A8A98C4D80D8664ECD"><enum>(d)</enum><header>Certification</header><text>The Chief Executive Officer or the company official responsible for negotiating any agreement required to be filed under subsection (a), (b), or (c) shall execute and file with the Assistant Attorney General and the Commission a certification as follows: <quote>I declare under penalty of perjury that the following is true and correct: The materials filed with the Federal Trade Commission and the Department of Justice under section 1112 of subtitle B of title XI of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, with respect to the agreement referenced in this certification: (1) represent the complete, final, and exclusive agreement between the parties; (2) include any ancillary agreements that are contingent upon, provide a contingent condition for, or are otherwise related to, the referenced agreement; and (3) include written descriptions of any oral agreements, representations, commitments, or promises between the parties that are responsive to subsection (a) or (b) of such section 1112 and have not been reduced to writing.</quote>.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></legis-body></bill>


